Clinical Grade Regulatory CD4(+) T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.
Clinical Grade Regulatory CD4(+) T Cells (Tregs): Moving Toward Cellular-Based Immunomodulatory Therapies.
复制标题
DOI：
10.3389/fimmu.2018.00252
复制
发表时间：
2018
影响因子：
7.3
通讯作者：
Saudemont A
中科院分区：
文献类型：
--
作者：
Duggleby R;Danby RD;Madrigal JA;Saudemont A
调节性 T 细胞 (Treg) 是 CD4+ T 细胞，是免疫耐受的关键参与者。它们是强大的抑制细胞，能够影响众多免疫细胞的功能，包括效应 T 细胞等炎症的关键效应细胞。因此，Tregs 是开发调节免疫反应的细胞治疗方法的理想候选者。迄今为止，Treg 疗法已显示出有希望的结果，提供了有关这些细胞可以提供保护的条件的关键知识，并证明它们可以成为当前药物免疫抑制疗法的替代方案。然而，需要更全面地了解它们的特征、隔离、激活和扩展，才能设计出具有成本效益的疗法。在这里，我们回顾了使 Tregs 成为可行的细胞疗法的实用性，特别是讨论了分离和制造 Tregs 所面临的挑战，并确定了这种新疗法最合适的应用。
Regulatory T cells (Tregs) are CD4+ T cells that are key players of immune tolerance. They are powerful suppressor cells, able to impact the function of numerous immune cells, including key effectors of inflammation such as effector T cells. For this reason, Tregs are an ideal candidate for the development of cell therapy approaches to modulate immune responses. Treg therapy has shown promising results so far, providing key knowledge on the conditions in which these cells can provide protection and demonstrating that they could be an alternative to current pharmacological immunosuppressive therapies. However, a more comprehensive understanding of their characteristics, isolation, activation, and expansion is needed to be able design cost effective therapies. Here, we review the practicalities of making Tregs a viable cell therapy, in particular, discussing the challenges faced in isolating and manufacturing Tregs and defining what are the most appropriate applications for this new therapy.